By contrast, the loss of FOXP1 expression has been observed in human glioma [16], prostate cancer [17], and renal cell carcinoma [18], and the loss of FOXP1 in breast cancer is correlated with lower survival rates [19]. This evidence concerns the gene FOXP1 and hereditary clear cell renal cell carcinoma.